Clinical trial · Interventional
Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant
Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): patients' reluctance
Summary
Brief summary (as posted)
The use of peripheral blood stem cells(PBSCs) is rapidly growing in the allogeneic transplantation setting as an alternative to bone marrow (BM).It was found that the use of PBSCs is associated with faster hematologic recovery but have yielded differing results regarding the incidence of graft-versus-host-disease (GVHD) and relapse. The study hypothesis: transplantation of mobilized PBSC to haploidentical donor with standard-risk leukemia had comparable engraftment and non-relapse mortality to mobilized BM combined with PBSCs
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| transplant with PBSCs | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- procedure/surgery
- description
- transplant with G-CSF mobilized PBSCs
- interventionNames
- Procedure: transplant with PBSCs
- type
- NO_INTERVENTION
- label
- other
- description
- no intervention after transplant with mobilized BMPB
Primary outcomes (1)
- measure
- incidence of engraftment
- timeFrame
- paticipants will be followed for the duration of hospital stay,an expected average of 30 days
- description
- number of participants with engraftment at 30d
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Standard risk of Recipients of haploidentical stem cell transplantation with myeloablative conditioning regimens Exclusion Criteria: * Active, uncontrolled infection
References
Publications (0)
Data not yet available